NVNO Key Statistics, Chart & Performance
The current stock price of NVNO is 10.42 USD. In the past month the price decreased by -13.46%. In the past year, price decreased by -90.33%.
NVNO Technical Analysis
NVNO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NVNO. While NVNO has a great health rating, there are worries on its profitability.
NVNO Financial Highlights
Over the last trailing twelve months NVNO reported a non-GAAP Earnings per Share(EPS) of -20.12. The EPS decreased by -1412.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.89% | ||
| ROE | -74.59% | ||
| Debt/Equity | 0 |
NVNO Forecast & Estimates
NVNO Ownership
NVNO Latest News, Press Relases and Analysis
NVNO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.33 | 189.676B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.14 | 168.855B | ||
| SYK | STRYKER CORP | 23.7 | 138.597B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.78 | 115.097B | ||
| BDX | BECTON DICKINSON AND CO | 13.98 | 58.942B | ||
| IDXX | IDEXX LABORATORIES INC | 43.51 | 51.391B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.59 | 45.321B | ||
| RMD | RESMED INC | 22.12 | 38.981B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.06 | 37.494B | ||
| DXCM | DEXCOM INC | 27.8 | 27.258B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVNO
Company Profile
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 37 full-time employees. The company went IPO on 2018-05-31. The firm is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The firm is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The firm is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Company Info
ENVVENO MEDICAL CORP
70 Doppler
Irvine CALIFORNIA US
CEO: Robert Berman
Employees: 37
Phone: 19492612900
ENVVENO MEDICAL CORP / NVNO FAQ
Can you describe the business of ENVVENO MEDICAL CORP?
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 37 full-time employees. The company went IPO on 2018-05-31. The firm is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The firm is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The firm is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
What is the current price of NVNO stock?
The current stock price of NVNO is 10.42 USD. The price increased by 11.44% in the last trading session.
Does ENVVENO MEDICAL CORP pay dividends?
NVNO does not pay a dividend.
What is the ChartMill rating of ENVVENO MEDICAL CORP stock?
NVNO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists NVNO stock?
NVNO stock is listed on the Nasdaq exchange.
Would investing in ENVVENO MEDICAL CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NVNO.
Can you provide the ownership details for NVNO stock?
You can find the ownership structure of ENVVENO MEDICAL CORP (NVNO) on the Ownership tab.